文献速递中医内科中药与中成药合理使用

金花清感颗粒联合奈玛特韦/利托那韦治疗高龄新冠患者疗效与安全性

Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study.
PubMed 文献 · J Integr Med · 2025-10-15

该回顾性队列纳入180例高龄COVID-19患者,比较单用奈玛特韦/利托那韦与联用金花清感颗粒的疗效与安全性。联用组5天内核酸转阴率更高(80.22% vs 66.29%,P=0.035),多因素分析显示联用与5天内转阴独立相关(OR=2.216,95%CI:1.066-4.607,P=0.033),且症状恢复更优,安全性无显著差异。

要点

  • 高龄COVID-19患者联用金花清感颗粒可提高5天内核酸转阴率
  • 联用组发热、咳嗽、咳痰等呼吸道症状恢复率及退热时间更优
  • 联用未增加不良反应发生率,肝肾功能指标无显著差异

核心结论

  • 在高龄COVID-19患者中,奈玛特韦/利托那韦联用金花清感颗粒可显著改善早期临床恢复且不增加安全性担忧。

研究设计与样本

  • 回顾性队列研究纳入2023年7月至2024年7月解放军总医院180例确诊COVID-19高龄患者,分为单药组(奈玛特韦/利托那韦,n=89)和联合组(奈玛特韦/利托那韦+金花清感颗粒,n=91)。

主要发现

  • 联合组5天内核酸转阴率显著高于单药组(80.22% vs 66.29%,P=0.035)。
  • 多因素分析显示联用金花清感颗粒与5天内核酸转阴显著相关(OR=2.216;95%CI:1.066-4.607;P=0.033)。
  • 联合组在发热、咳嗽、咳痰及所有呼吸道症状恢复率和退热时间上均优于单药组(P<0.05)。
  • 两组C反应蛋白改善有显著差异(P<0.05)。
  • 两组不良反应发生率及肝肾功能指标无显著差异(P>0.05)。

关键数值与推荐

  • 主要结局为治疗开始后第5天累积核酸转阴率,联合组80.22%、单药组66.29%(P=0.035)。
  • 多因素分析联用金花清感颗粒的OR=2.216(95%CI:1.066-4.607;P=0.033)。

临床怎么用

  • 对高龄COVID-19患者,在奈玛特韦/利托那韦基础上可考虑联用金花清感颗粒以促进早期核酸转阴和症状恢复。
  • 联用方案未增加不良反应及肝肾功能损害,但仍需结合患者个体情况评估。

局限性

  • 本研究为单中心回顾性队列研究,样本量有限且以男性为主(94.44%),结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited data are available on the use of antiviral drugs among oldest-old patients. This study investigates the effect of Jinhua Qinggan Granule (JHQG), a compound Chinese herbal medicine, on the efficacy and safety of nirmatrelvir/ritonavir in oldest-old patients with coronavirus disease 2019 (COVID-19). METHODS: A total of 180 oldest-old patients with confirmed COVID-19 at the Chinese PLA General Hospital from July 2023 to July 2024 were enrolled in this retrospective cohort study and were divided into a monotherapy group (nirmatrelvir/ritonavir, n = 89) and a combination therapy group (nirmatrelvir/ritonavir plus JHQG, n = 91) according to the treatments received. The primary outcome was the cumulative rate of nucleic acid negative conversion (NANC) on the fifth day after initiation of treatment. The secondary outcomes included the rates of improvement in the main symptoms, the duration of fever, and variations in clinical laboratory indices. The safety outcomes included the incidence of adverse drug reactions (ADRs) and indicators of liver and kidney function. RESULTS: Among the 180 oldest-old patients participating in the study, the median (P25, P75) age was 93.0 (86.0, 96.0) years, and 94.44% were male. The rate of NANC within five days was significantly higher in the combination therapy group than in the monotherapy group (80.22% vs 66.29%, P = 0.035). The addition of JHQG was significantly associated with NANC within five days in the multivariable analysis (odds ratio [OR] = 2.216; 95% confidence interval [CI]: 1.066-4.607; P = 0.033). Furthermore, compared with nirmatrelvir/ritonavir alone, combination therapy had better effects on the recovery rates of various symptoms, including fever, cough, expectoration, and all respiratory symptoms, as well as the time to recovery from fever (P < 0.05). There were also significant differences between the two groups in terms of improvement in C-reactive protein (P < 0.05). Moreover, no significant differences were observed in the incidence of ADRs or in liver and kidney function indicators (P > 0.05). CONCLUSION: Among oldest-old patients with COVID-19, the addition of JHQG to nirmatrelvir/ritonavir significantly improves early clinical recovery without increasing safety concerns. Please cite this article as: Chen LL, Zhai WJ, Bao J, Yu ZH, Zhang TY, Lu XC, Liu L, Chen L, Wang SY, Hu J, Gao X, Zhang Q, Xu GG, Xin HL. Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study. J Integr Med. 2026; 24(4):566-572.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Chen LL, Zhai WJ, Bao J, et al. Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study. J Integr Med. 2025. PMID: 41203485. doi:10.1016/j.joim.2025.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。